An update on local and systemic therapies for nonmelanoma skin cancer

References

• Albert MR, Weinstock MAKC. CA. Cancer J Clinicians 2003;53(5):292–302.
   Google Scholar
• Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatol. 2015;151(10):1081–1086.
   PubMed Web of Science ®Google Scholar
• Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer. 1998;78(2):144–148.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105(5):350–360.
   PubMedGoogle Scholar
• Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–720.
   PubMed Web of Science ®Google Scholar
• Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457–463 e452.
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Chatterjee K, Pandhi D, et al. Basal cell carcinoma: pathophysiology. Skinmed. 2014;12(3):176–181.
   PubMedGoogle Scholar
• Schmults CD, Blitzblau R, Aasi SZ, et al. NCCN Clinical Practice Guidelines in Oncology: Basal Cell Carcinoma. Version 1.2022. Available at: NCCN.org. Accessed January 19, 2022.
   Google Scholar
• Dieu T, Macleod AM. Incomplete excision of basal cell carcinomas: a retrospective audit. ANZ J Surg. 2002;72(3):219–221.
   PubMed Web of Science ®Google Scholar
• Bogdanov-Berezovsky A, Cohen A, Glesinger R, et al. Clinical and pathological findings in reexcision of incompletely excised basal cell carcinomas. Ann Plast Surg. 2001;47:299–302.
   PubMed Web of Science ®Google Scholar
• Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. J Dermatol Surg Oncol. 1992;18(6):471–476.
   PubMedGoogle Scholar
• Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006;45(5):489–498.
   PubMed Web of Science ®Google Scholar
• Sebaratnam DF, Choy B, Lee M, et al. Direct cost-analysis of Mohs micrographic surgery and traditional excision for basal cell carcinoma at initial margin clearance. Dermatol Surg. 2016;42(5):633–638.
   PubMed Web of Science ®Google Scholar
• Cook JL, Perone JB. A prospective evaluation of the incidence of complications associated with Mohs micrographic surgery. Arch Dermatol. 2003;139(2):143–152.
   PubMedGoogle Scholar
• van Loo E, Mosterd K, Krekels GAM, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011–3020.
   PubMed Web of Science ®Google Scholar
• Tanese K. Diagnosis and management of basal cell carcinoma. Curr Treat Options Oncol. 2019;20(2):13.
   PubMed Web of Science ®Google Scholar
• Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720–726.
   PubMedGoogle Scholar
• Drucker AM, Adam GP, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. Ann Intern Med. 2018;169(7):456–466.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Cryosurgery in dermatology. Eur J Dermatol. 1998;8(7):466–474.
   PubMed Web of Science ®Google Scholar
• Thissen MR, Nieman FH, Ideler AH, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000;26(8):759–764.
   PubMed Web of Science ®Google Scholar
• Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol. 2011;25(8):896–901.
   PubMed Web of Science ®Google Scholar
• Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas. Part 4: x-ray therapy. J Dermatol Surg Oncol. 1992;18(7):549–554.
   PubMedGoogle Scholar
• Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390–398.
   PubMed Web of Science ®Google Scholar
• Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647–654.
   PubMed Web of Science ®Google Scholar
• McKay K, Sambrano B, Fox P, et al. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness‐based definition of sBCC. Br J Dermatol. 2013;169(3):549–554.
   PubMed Web of Science ®Google Scholar
• Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105.
   PubMed Web of Science ®Google Scholar
• Zhu H, Lewis DJ. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we? Expert Opin Pharmacother. 2022;23(6):739–740. DOI:https://doi.org/10.1080/14656566.2022.2050215
   PubMedGoogle Scholar
• Cosio T, Di Prete M, Di Raimondo C, et al. Patidegib in dermatology: a current review. Int J Mol Sci. 2021;22(19):10725.
   PubMed Web of Science ®Google Scholar
• Villani A, Cinelli E, Fabbrocini G, et al. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020;19(12):1585–1594.
   PubMed Web of Science ®Google Scholar
• Bakshi A, Chaudhary SC, Rana M, et al. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 2017;56(12):2543–2557.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Maturo MG, Di Nardo L, et al. Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci. 2017;18(11):2485.
   PubMed Web of Science ®Google Scholar
• Jacobsen AA, Aldahan AS, Hughes OB, et al. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152(7):816–824.
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Expert opinion on sonidegib efficacy, safety and tolerability. Expert Opin Drug Saf. 2021;20(8):877–882.
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–1378.
   PubMed Web of Science ®Google Scholar
• Xie P, Lefrancois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(6):1089–1100. e1017.
   PubMed Web of Science ®Google Scholar
• Basset-Seguin N, Hauschild A, Grob -J-J, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–736.
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from basal cell carcinoma outcomes with lde225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016;75(1):113–125.e115.
   PubMed Web of Science ®Google Scholar
• Chang ALS, Oro AE. initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–1325.
   PubMedGoogle Scholar
• Cosio T, Di Prete M, Campione E. Arsenic Trioxide, Itraconazole, All-trans retinoic acid and nicotinamide: a proof of concept for combined treatments with hedgehog inhibitors in advanced basal cell carcinoma. Biomedicines. 2020;8(6):156.
   PubMed Web of Science ®Google Scholar
• Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):848–857.
   PubMed Web of Science ®Google Scholar
• Büttner R, Longshore JW, López-Ríos F, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1):e000442.
   PubMed Web of Science ®Google Scholar
• Lewis K, Peris K, Sekulic A, et al. 428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). J Immunother Cancer. 2020;8(Suppl 3):A260–A261.
   Google Scholar
• Schmults CD, Blitzblau R, Aasi SZ, et al. NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 1.2022. Available at: NCCN.org. Accessed January 19, 2022.
   Google Scholar
• Picard A, Pedeutour F, Peyrade F, et al. Association of oncogenic mutations in patients with advanced cutaneous squamous cell carcinomas treated with cetuximab. JAMA Dermatol. 2017;153(4):291–298.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Kogay M, Viotti J, et al. Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective: a real-life analysis. Ann Oncol. 2018;29:viii462.
   Web of Science ®Google Scholar
• Chren MM, Linos E, Torres JS, et al. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013;133(5):1188–1196.
   PubMed Web of Science ®Google Scholar
• Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg. 2013;15(5):337–343.
   PubMed Web of Science ®Google Scholar
• Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol. 2002;138(8):1043–1051.
   PubMedGoogle Scholar
• Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol. 2005;53(2):253–260.
   PubMed Web of Science ®Google Scholar
• Xiong DD, Beal BT, Varra V, et al. Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision. J Am Acad Dermatol. 2020;82(5):1195–1204.
   PubMed Web of Science ®Google Scholar
• Marrazzo G, Zitelli JA, Brodland D. Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone. J Am Acad Dermatol. 2019;80(3):633–638.
   PubMed Web of Science ®Google Scholar
• Allen JE, Stolle LB. Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol. 2015;41(2):197–200.
   PubMed Web of Science ®Google Scholar
• Kofler L, Kofler K, Schulz C, et al. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma. Arch Dermatol Res. 2021;313(2):119–126.
   PubMed Web of Science ®Google Scholar
• Wysong A, Newman JG, Covington KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2021;84(2):361–369.
   PubMed Web of Science ®Google Scholar
• Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60(2):406–411.
   PubMed Web of Science ®Google Scholar
• Barysch MJ, Eggmann N, Beyeler M, et al. Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy. Dermatology. 2012;224(1):59–65.
   PubMed Web of Science ®Google Scholar
• Schulte KW, Lippold A, Auras C, et al. Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol. 2005;53(6):993–1001.
   PubMed Web of Science ®Google Scholar
• Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American society for radiation oncology clinical practice guideline. Pract Radiat Oncol. 2020;10(1):8–20.
   PubMed Web of Science ®Google Scholar
• Searle T, Ali FR, Al-Niaimi F. Intralesional methotrexate in dermatology: diverse indications and practical considerations. Dermatol Ther. 2021;34(1):e14404.
   PubMed Web of Science ®Google Scholar
• Salido-Vallejo R, Cuevas-Asencio I, Garnacho-Sucedo G, et al. Neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: a comparative cohort study. J Eur Acad Dermatol Venereol. 2016;30(7):1120–1124.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351.
   PubMed Web of Science ®Google Scholar
• Barnett R, Barta VS, Jhaveri KD. Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab. N Engl J Med. 2017;376(2):191–192.
   PubMed Web of Science ®Google Scholar
• Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32(10):1276–1285.
   PubMed Web of Science ®Google Scholar
• Galer CE, Corey CL, Wang Z, et al. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck. 2011;33(2):189–198.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Erbitux (cetuximab) [product monograph]. Indianapolis (IN): Eli Lilly and Company; 2021.
   Google Scholar
• Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–3426.
   PubMed Web of Science ®Google Scholar
• Claveau J, Archambault J, Ernst DS, et al. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma. Curr Oncol. 2020;27(4):e399–e407.
   PubMed Web of Science ®Google Scholar
• Tarantola TI, Vallow LA, Halyard MY, et al. Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol. 2013;68(3):425–432.
   PubMed Web of Science ®Google Scholar
• Yiengpruksawan A, Coit DG, Thaler HT, et al. Merkel cell carcinoma: prognosis and management. Arch Surg. 1991;126(12):1514–1519.
   PubMedGoogle Scholar
• BR SCD, Aasi SZ, et al. NCCN clinical practice guidelines in oncology: Merkel cell carcinoma.version 1.2022. Available at: NCCN.org. Accessed 2022. 2022 Jan 25.
   Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther (Heidelb). 2019;9(2):209–222.
   PubMed Web of Science ®Google Scholar
• Perez MC, de Pinho FR, Holstein A, et al. Resection margins in Merkel cell carcinoma: is a 1-cm margin wide enough? Ann Surg Oncol. 2018;25(11):3334–3340.
   PubMed Web of Science ®Google Scholar
• Singh B, Qureshi MM, Truong MT, et al. Demographics and outcomes of stage I and II Merkel cell carcinoma treated with mohs micrographic surgery compared with wide local excision in the national cancer database. J Am Acad Dermatol. 2018;79(1):126–134.e123.
   PubMed Web of Science ®Google Scholar
• Farley CR, Perez MC, Soelling SJ, et al. Merkel Cell Carcinoma Outcomes: does AJCC8 Underestimate Survival? Ann Surg Oncol. 2020;27(6):1978–1985.
   PubMed Web of Science ®Google Scholar
• Smith FO, Yue B, Marzban SS, et al. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer. 2015;121(18):3252–3260.
   PubMed Web of Science ®Google Scholar
• Perez MC, Oliver DE, Weitman ES, et al. Management of sentinel lymph node metastasis in Merkel cell carcinoma: completion lymphadenectomy, radiation, or both? Ann Surg Oncol. 2019;26(2):379–385.
   PubMed Web of Science ®Google Scholar
• Pape E, Rezvoy N, Penel N, et al. Radiotherapy alone for Merkel cell carcinoma: a comparative and retrospective study of 25 patients. J Am Acad Dermatol. 2011;65(5):983–990.
   PubMed Web of Science ®Google Scholar
• Bichakjian CK, Olencki T, Aasi SZ, et al. Merkel Cell Carcinoma,Version 1.2018,NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(6):742–774.
   PubMed Web of Science ®Google Scholar
• Strom T, Carr M, Zager JS, et al. Radiation Therapy is associated with improved outcomes in Merkel cell carcinoma. Ann Surg Oncol. 2016;23(11):3572–3578.
   PubMed Web of Science ®Google Scholar
• Cimbak NC, Barker CA. Short-course radiation therapy for Merkel cell carcinoma: relative effectiveness in a radiosensitive tumor. Int J Radiat Oncol. 2016;96:S160.
   Google Scholar
• Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol. 2007;25(9):1043–1047.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Storer BE, Iyer JG, et al. Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the national cancer data base. J Natl Cancer Inst. 2016;108(9):djw042.
   PubMedGoogle Scholar
• Esposito A, Jacobs D, Ariyan S, et al. Merkel cell carcinoma: changing practice patterns and impact on recurrence-free and overall survival at a single institution and nationally. Ann Surg Oncol. 2021;28:736–737.
   Web of Science ®Google Scholar
• BS DSP, Brohl AS, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;8:e000674.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Bhatia S, Hollebecque A, et al. Abstract CT074: non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). In: AACR; 2017.
   Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016;374(26):2542–2552.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;8(1):e000674. DOI:https://doi.org/10.1136/jitc-2020-000674
   PubMed Web of Science ®Google Scholar
• Nghiem P, Bhatia S, Lipson EJ, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37(9):693–702.
   PubMed Web of Science ®Google Scholar
• Turaga KK, Beasley GM, Kane JM 3rd, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg. 2011;146(7):870–875.
   PubMedGoogle Scholar
• O’Donoghue C, Perez MC, Mullinax JE, et al. Isolated Limb Infusion: a Single-Center Experience with Over 200 Infusions. Ann Surg Oncol. 2017;24(13):3842–3849.
   PubMed Web of Science ®Google Scholar
• Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904–911.e901.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the checkmate 358 trial. J Clin Oncol. 2020;38(22):2476–2487.
   PubMed Web of Science ®Google Scholar